Two of the world's leading medtech companies have been collaborating to improve patient access to CGM technology. It now looks like Medtronic and Abbott could be close to gaining FDA clearance and moving forward to the next phase of their partnership.

The advanced machine learning model tracks more than 50 different factors to make its predictions. It has already been found to be more accurate than popular prediction methods for heart disease that are currently available. 

The study's authors focused on blood pressure reductions and arterial stiffness, sharing their findings in Current Developments in Nutrition.

Researchers focused on data from nearly 78,000 adults with cardiometabolic disorders, sharing their findings at ACC.25 in Chicago.

Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.